{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:20:21Z","timestamp":1791404421926,"version":"4.3.3"},"reference-count":129,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1053\/j.seminhematol.2024.12.001","type":"journal-article","created":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T11:12:38Z","timestamp":1735557158000},"page":"58-70","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Advancements in bispecific antibodies for multiple myeloma: What's new and what lies ahead"],"prefix":"10.1053","volume":"62","author":[{"given":"Tarek H.","family":"Mouhieddine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno Almeida","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0274-0585","authenticated-orcid":false,"given":"Joshua","family":"Richter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1053\/j.seminhematol.2024.12.001_bib0001","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1016\/S1470-2045(20)30756-7","article-title":"Treatment of relapsed and refractory multiple myeloma: recommendations from the international myeloma working group","volume":"22","author":"Moreau","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.seminhematol.2024.12.001_bib0002","unstructured":"SEER*Explorer: An interactive website for SEER cancer statistics [Internet]. Surveillance Research Program, National Cancer Institute; 2024 Apr 17. [updated: 2024 Nov 5; cited 2025 Jan 17]. Available from: https:\/\/seer.cancer.gov\/statistics-network\/explorer\/. Data source(s): SEER Incidence Data, November 2023 Submission (1975-2021), SEER 22 registries (excluding Illinois and Massachusetts). Expected Survival Life Tables by Socio-Economic Standards."},{"issue":"10396","key":"10.1053\/j.seminhematol.2024.12.001_bib0003","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S0140-6736(23)00521-4","article-title":"T-cell-engaging bispecific antibodies in cancer","volume":"402","author":"van de Donk","year":"2023","journal-title":"Lancet"},{"key":"10.1053\/j.seminhematol.2024.12.001_bib0004","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","author":"Moreau","year":"2022","journal-title":"New Eng J Med"},{"issue":"24","key":"10.1053\/j.seminhematol.2024.12.001_bib0005","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"New Eng J Med"},{"issue":"10","key":"10.1053\/j.seminhematol.2024.12.001_bib0006","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1038\/s41591-023-02589-w","article-title":"Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial","volume":"29","author":"Bahlis","year":"2023","journal-title":"Nat Med"},{"issue":"9","key":"10.1053\/j.seminhematol.2024.12.001_bib0007","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"issue":"11","key":"10.1053\/j.seminhematol.2024.12.001_bib0008","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1080\/14712598.2019.1641196","article-title":"B cell maturation antigen (BCMA)-based immunotherapy for multiple myeloma","volume":"19","author":"Tai","year":"2019","journal-title":"Expert Opin Biol Ther"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.12.001_bib0009","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1615\/CritRevImmunol.v32.i4.10","article-title":"Regulatory roles of the tumor necrosis factor receptor BCMA","volume":"32","author":"Coquery","year":"2012","journal-title":"Crit Rev Immunol"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.12.001_bib0010","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/s41408-021-00505-4","article-title":"Serum BCMA levels predict outcomes in MGUS and smoldering myeloma patients","volume":"11","author":"Visram","year":"2021","journal-title":"Blood Cancer J"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.12.001_bib0011","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1093\/cei\/uxae043","article-title":"Elevated serum levels of soluble B-cell maturation antigen as a prognostic biomarker for multiple myeloma","volume":"217","author":"Guo","year":"2024","journal-title":"Clin Exp Immunol"},{"key":"10.1053\/j.seminhematol.2024.12.001_bib0012","doi-asserted-by":"crossref","first-page":"7333","DOI":"10.1038\/ncomms8333","article-title":"gamma-secretase directly sheds the survival receptor BCMA from plasma cells","volume":"6","author":"Laurent","year":"2015","journal-title":"Nat Commun"},{"issue":"8","key":"10.1053\/j.seminhematol.2024.12.001_bib0013","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41408-022-00716-3","article-title":"gamma-secretase inhibitors augment efficacy of BCMA-targeting bispecific antibodies against multiple myeloma cells without impairing T-cell activation and differentiation","volume":"12","author":"Chen","year":"2022","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.12.001_bib0014","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41408-023-00966-9","article-title":"GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review","volume":"14","author":"Rodriguez-Otero","year":"2024","journal-title":"Blood cancer J"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.12.001_bib0015","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0167-4781(01)00197-X","article-title":"Cloning and characterization of a human orphan family C G-protein coupled receptor GPRC5D","volume":"1518","author":"Brauner-Osborne","year":"2001","journal-title":"Biochimica et biophysica acta"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.12.001_bib0016","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1046\/j.0022-202X.2004.12628.x","article-title":"The RAIG family member, GPRC5D, is associated with hard-keratinized structures","volume":"122","author":"Inoue","year":"2004","journal-title":"J Invest Dermatol"},{"issue":"9","key":"10.1053\/j.seminhematol.2024.12.001_bib0017","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1111\/j.1365-2362.2012.02679.x","article-title":"Overexpression of G protein-coupled receptor 5D in the bone marrow is associated with poor prognosis in patients with multiple myeloma","volume":"42","author":"Atamaniuk","year":"2012","journal-title":"Eur J Clin Invest"},{"issue":"485","key":"10.1053\/j.seminhematol.2024.12.001_bib0018","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau7746","article-title":"GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells","volume":"11","author":"Smith","year":"2019","journal-title":"Sci Transl Med"},{"issue":"15","key":"10.1053\/j.seminhematol.2024.12.001_bib0019","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1182\/blood.2019003342","article-title":"A T-cell-redirecting bispecific G-protein-coupled receptor class 5 member D x CD3 antibody to treat multiple myeloma","volume":"135","author":"Pillarisetti","year":"2020","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2024.12.001_bib0020","first-page":"1948","author":"Dekhtiarenko","year":"2023"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.12.001_bib0021","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1189\/jlb.0211096","article-title":"Fc receptor-like 5 promotes B cell proliferation and drives the development of cells displaying switched isotypes","volume":"91","author":"Dement-Brown","year":"2012","journal-title":"J Leukoc Biol"},{"issue":"9","key":"10.1053\/j.seminhematol.2024.12.001_bib0022","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1093\/intimm\/dxl069","article-title":"Expression pattern of the human FcRH\/IRTA receptors in normal tissue and in B-chronic lymphocytic leukemia","volume":"18","author":"Polson","year":"2006","journal-title":"Int Immunol"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.12.001_bib0023","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.trecan.2019.11.005","article-title":"Targeting NAD(+) synthesis to potentiate CD38-based immunotherapy of Multiple myeloma","volume":"6","author":"Kennedy","year":"2020","journal-title":"Trends Cancer"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.12.001_bib0024","first-page":"260","article-title":"Preclinical characterization of ISB 1342, a CD38 x CD3 T-cell engager for relapsed\/refractory multiple myeloma","volume":"142","author":"Pouleau","year":"2023","journal-title":"Blood"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.12.001_bib0025","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.3324\/haematol.2019.242453","article-title":"Bi38-3 is a novel CD38\/CD3 bispecific T-cell engager with low toxicity for the treatment of multiple myeloma","volume":"106","author":"Fayon","year":"2021","journal-title":"Haematologica"},{"issue":"13","key":"10.1053\/j.seminhematol.2024.12.001_bib0026","doi-asserted-by":"crossref","first-page":"3921","DOI":"10.1158\/1078-0432.CCR-18-2752","article-title":"Targeting multiple myeloma with AMG 424, a novel Anti-CD38\/CD3 bispecific T-cell-recruiting antibody optimized for cytotoxicity and cytokine release","volume":"25","author":"Zuch de Zafra","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.12.001_bib0027","article-title":"A bispecific T cell engager recruits both type 1 NKT and Vgamma9Vdelta2-T cells for the treatment of CD1d-expressing hematological malignancies","volume":"4","author":"Lameris","year":"2023","journal-title":"Cell Rep Med"},{"issue":"11","key":"10.1053\/j.seminhematol.2024.12.001_bib0028","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/s43018-020-00111-6","article-title":"A single-domain bispecific antibody targeting CD1d and the NKT T-cell receptor induces a potent antitumor response","volume":"1","author":"Lameris","year":"2020","journal-title":"Nat Cancer"},{"issue":"7","key":"10.1053\/j.seminhematol.2024.12.001_bib0029","article-title":"A target discovery pipeline identified ILT3 as a target for immunotherapy of multiple myeloma","volume":"4","author":"Di Meo","year":"2023","journal-title":"Cell Rep Med"},{"issue":"7","key":"10.1053\/j.seminhematol.2024.12.001_bib0030","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1158\/2326-6066.CIR-17-0649","article-title":"A CS1-NKG2D bispecific antibody collectively activates cytolytic immune cells against multiple myeloma","volume":"6","author":"Chan","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"10.1053\/j.seminhematol.2024.12.001_bib0031","series-title":"CTX-8573, an innate-cell engager targeting BCMA, is a highly potent multispecific antibody for the treatment of multiple myeloma","first-page":"3182","author":"Watkins-Yoon","year":"2019"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.12.001_bib0032","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/CJI.0000000000000320","article-title":"BCMA-targeting bispecific antibody that simultaneously stimulates NKG2D-enhanced efficacy against multiple myeloma","volume":"43","author":"Wang","year":"2020","journal-title":"J Immunother"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.12.001_bib0033","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/s43018-019-0004-z","article-title":"Trispecific antibodies enhance the therapeutic efficacy of tumor-directed T cells through T cell receptor co-stimulation","volume":"1","author":"Wu","year":"2020","journal-title":"Nat Cancer"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.12.001_bib0034","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1158\/2767-9764.CRC-23-0434","article-title":"Ex vivo efficacy of SAR442257 anti-CD38 trispecific T-cell engager in multiple myeloma relapsed after Daratumumab and BCMA-targeted therapies","volume":"4","author":"Keller","year":"2024","journal-title":"Cancer Res Commun"},{"issue":"9","key":"10.1053\/j.seminhematol.2024.12.001_bib0035","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/protein\/gzx043","article-title":"Trispecific antibodies for CD16A-directed NK cell engagement and dual-targeting of tumor cells","volume":"30","author":"Gantke","year":"2017","journal-title":"Protein Eng Des Sel"},{"key":"10.1053\/j.seminhematol.2024.12.001_bib0036","series-title":"A novel tri-specific t cell engager targeting BCMA and GPRC5D for treatment of multiple myeloma","author":"Tan","year":"2024"},{"key":"10.1053\/j.seminhematol.2024.12.001_bib0037","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1038\/s43018-024-00821-1","article-title":"ISB 2001 trispecific T cell engager shows strong tumor cytotoxicity and overcomes immune escape mechanisms of multiple myeloma cells","volume":"5","author":"Carretero-Iglesia","year":"2024","journal-title":"Nat Cancer"},{"issue":"10301","key":"10.1053\/j.seminhematol.2024.12.001_bib0038","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(21)01338-6","article-title":"Teclistamab, a B-cell maturation antigen x CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study","volume":"398","author":"Usmani","year":"2021","journal-title":"Lancet"},{"key":"10.1053\/j.seminhematol.2024.12.001_bib0039","series-title":"Long-term follow-up from majestec-1 of teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma (RRMM)","author":"van de Donk","year":"2023"},{"key":"10.1053\/j.seminhematol.2024.12.001_bib0040","series-title":"Long-term follow-up from the phase 1\/2 majestec-1 trial of teclistamab in patients with relapsed\/refractory multiple myeloma","first-page":"7540","author":"Garfall","year":"2024"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.12.001_bib0041","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/cncr.35107","article-title":"Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed\/refractory multiple myeloma in the MajesTEC-1 study","volume":"130","author":"Nooka","year":"2024","journal-title":"Cancer"},{"key":"10.1053\/j.seminhematol.2024.12.001_bib0042","first-page":"S561","article-title":"Long-term efficacy and safety results from the phase 1\/2 MonumenTAL-1 study of Talquetamab, a GPRC5D\u00d7CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma. IMS","volume":"24","author":"Rasche","year":"2024","journal-title":"Rio De Janeiro: Clinical Lymphoma Myeloma and Leukemia"},{"key":"10.1053\/j.seminhematol.2024.12.001_bib0043","first-page":"S1","article-title":"Prophylactic interventions for oral toxicities with the GPRC5D\u00d7CD3 bispecific antibody Talquetamab in relapsed\/refractory multiple myeloma: aan open-label, phase 2, randomized study (TALISMAN). IMS","volume":"24","author":"Popat","year":"2024","journal-title":"Rio de Janeiro: Clinical Lymphoma Myeloma and Leukemia"},{"issue":"7","key":"10.1053\/j.seminhematol.2024.12.001_bib0044","first-page":"e136","volume":"8","author":"Tomasson","year":"2024","journal-title":"Long-term survival and safety of elranatamab in patients with relapsed or refractory multiple myeloma: update from the magnetismm-3 study"},{"issue":"22","key":"10.1053\/j.seminhematol.2024.12.001_bib0045","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1200\/JCO.24.01008","article-title":"Linvoseltamab for treatment of relapsed\/refractory multiple myeloma","volume":"42","author":"Bumma","year":"2024","journal-title":"J Clin Oncol: official journal of the American Society of Clinical Oncology"},{"issue":"31","key":"10.1053\/j.seminhematol.2024.12.001_bib0046","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1200\/JCO.22.01504","article-title":"A phase I first-in-Human study of ABBV-383, a B-cell maturation antigen x CD3 bispecific T-cell redirecting antibody, in patients with relapsed\/refractory multiple myeloma","volume":"40","author":"D'Souza","year":"2022","journal-title":"J Clin Oncol: official journal of the American Society of Clinical Oncology"},{"key":"10.1053\/j.seminhematol.2024.12.001_bib0047","first-page":"3378","article-title":"Updated safety and efficacy results of Abbv-383, a BCMA x CD3 bispecific T-cell redirecting antibody, in a first-in-Human phase 1 study in patients with relapsed\/refractory multiple myeloma","volume":"142","author":"Vij","year":"2023","journal-title":"ASH. San Diego: Blood"},{"issue":"16_suppl","key":"10.1053\/j.seminhematol.2024.12.001_bib0048","doi-asserted-by":"crossref","first-page":"7531","DOI":"10.1200\/JCO.2024.42.16_suppl.7531","article-title":"Efficacy, safety, and determination of RP2D of ABBV-383, a BCMA bispecific antibody, in patients with relapsed\/refractory multiple myeloma (RRMM)","volume":"42","author":"Valdes","year":"2024","journal-title":"Journal of Clinical Oncology"},{"issue":"8_Supplement","key":"10.1053\/j.seminhematol.2024.12.001_bib0049","doi-asserted-by":"crossref","first-page":"CT013","DOI":"10.1158\/1538-7445.AM2023-CT013","article-title":"Abstract CT013: ssafety and efficacy from the phase 1\/2 first-in-human study of REGN5459, a BCMA\u00d7CD3 bispecific antibody with low CD3 affinity, in patients with relapsed\/refractory multiple myeloma","volume":"83","author":"Suvannasankha","year":"2023","journal-title":"Cancer research"},{"key":"10.1053\/j.seminhematol.2024.12.001_bib0050","series-title":"Results from a first-in-human phase i study of F182112, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma","author":"Sun","year":"2023"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2024.12.001_bib0051","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1182\/blood-2023-180013","volume":"142","author":"Bar","year":"2023","journal-title":"Blood"},{"issue":"8","key":"10.1053\/j.seminhematol.2024.12.001_bib0052","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1200\/JCO.19.02657","article-title":"Anti-B-cell maturation antigen BiTE molecule AMG 420 induces responses in multiple myeloma","volume":"38","author":"Topp","year":"2020","journal-title":"J Clin Oncol: official journal of the American Society of Clinical Oncology"},{"issue":"17","key":"10.1053\/j.seminhematol.2024.12.001_bib0053","doi-asserted-by":"crossref","first-page":"4180","DOI":"10.1182\/bloodadvances.2020002565","article-title":"AMG 701 induces cytotoxicity of multiple myeloma cells and depletes plasma cells in cynomolgus monkeys","volume":"4","author":"Goldstein","year":"2020","journal-title":"Blood Adv"},{"key":"10.1053\/j.seminhematol.2024.12.001_bib0054","series-title":"Relapsed\/Refractory (RR) multiple myeloma (MM)","first-page":"28","article-title":"A phase 1 first in Human (FIH) study of AMG 701, an anti-B-cell maturation antigen (BCMA) half-life extended (HLE) BiTE\u00ae (bispecific T-cell engager) molecule","author":"Harrison","year":"2020"},{"key":"10.1053\/j.seminhematol.2024.12.001_bib0055","series-title":"Efficacy of forimtamig, a GPRC5DxCD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma (RRMM): analysis of patient and disease-related factors associated with responses","author":"Harrison","year":"2023"},{"key":"10.1053\/j.seminhematol.2024.12.001_bib0056","series-title":"Cevostamab monotherapy continues to show clinically meaningful activity and manageable safety in patients with heavily pre-treated relapsed\/refractory multiple myeloma (RRMM): updated results from an ongoing phase i study","first-page":"157","author":"Trudel","year":"2021"},{"issue":"16_suppl","key":"10.1053\/j.seminhematol.2024.12.001_bib0057","doi-asserted-by":"crossref","first-page":"TPS8069","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS8069","article-title":"CAMMA 1: a multicenter phase Ib trial evaluating the safety, pharmacokinetics, and activity of cevostamab-containing regimens in patients with relapsed or refractory multiple myeloma","volume":"40","author":"Vij","year":"2022","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10.1053\/j.seminhematol.2024.12.001_bib0058","doi-asserted-by":"crossref","first-page":"TPS8064","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS8064","article-title":"CAMMA 2: a phase I\/II trial evaluating the efficacy and safety of cevostamab in patients with relapsed\/refractory multiple myeloma (RRMM) who have triple-class refractory disease and have received a prior anti-B-cell maturation antigen (BCMA) agent","volume":"41","author":"Kumar","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2024.12.001_bib0059","unstructured":"Kumar S., Berdeja J., Sborov D., et al. Cevostamab in patients with RRMM who are triple-class refractory and have received a prior BCMA-targeted ADC or CAR T-cell: iinitial results from the phase I\/II CAMMA 2 study. EHA: EHA Library; 2024:S210."},{"issue":"8","key":"10.1053\/j.seminhematol.2024.12.001_bib0060","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1182\/bloodadvances.2020003805","article-title":"Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma","volume":"5","author":"Verkleij","year":"2021","journal-title":"Blood Adv"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.12.001_bib0061","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1182\/blood.2023022823","article-title":"Correlation of immune fitness with response to teclistamab in relapsed\/refractory multiple myeloma in the MajesTEC-1 study","volume":"144","author":"Cortes-Selva","year":"2024","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2024.12.001_bib0062","series-title":"Teclistamab (TEC)\u202f+\u202fnirogacestat (NIRO) in relapsed\/refractory multiple myeloma (RRMM): the phase 1b majestec-2 study","author":"Offner","year":"2023"},{"issue":"19","key":"10.1053\/j.seminhematol.2024.12.001_bib0063","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1182\/blood.2019000050","article-title":"\u03b3-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma","volume":"134","author":"Pont","year":"2019","journal-title":"Blood"},{"issue":"13","key":"10.1053\/j.seminhematol.2024.12.001_bib0064","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1182\/bloodadvances.2019001346","article-title":"CRISPR-based screens uncover determinants of immunotherapy response in multiple myeloma","volume":"4","author":"Ramkumar","year":"2020","journal-title":"Blood Adv"},{"key":"10.1053\/j.seminhematol.2024.12.001_bib0065","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1038\/s41591-023-02491-5","article-title":"Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma","volume":"29","author":"Lee","year":"2023","journal-title":"Nat Med"},{"issue":"13","key":"10.1053\/j.seminhematol.2024.12.001_bib0066","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2209900","article-title":"GPRC5D-Targeted CAR T cells for myeloma","volume":"387","author":"Mailankody","year":"2022","journal-title":"New Eng J Med"},{"issue":"11","key":"10.1053\/j.seminhematol.2024.12.001_bib0067","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1038\/s43018-023-00625-9","article-title":"Acquired resistance to a GPRC5D-directed T-cell engager in multiple myeloma is mediated by genetic or epigenetic target inactivation","volume":"4","author":"Derrien","year":"2023","journal-title":"Nat Cancer"},{"key":"10.1053\/j.seminhematol.2024.12.001_bib0068","first-page":"S1","article-title":"Impaired membrane trafficking of GPRC5D mediates resistance to Anti-GPRC5D TCE. IMS","volume":"24","author":"Lee","year":"2024","journal-title":"Rio de Janeiro: Clinical Lymphoma Myeloma and Leukemia"},{"key":"10.1053\/j.seminhematol.2024.12.001_bib0069","article-title":"Timing antigenic escape in multiple myeloma treated with T-cell redirecting immunotherapies","author":"Papadimitriou","year":"2024","journal-title":"bioRxiv"},{"key":"10.1053\/j.seminhematol.2024.12.001_bib0070","first-page":"S1","article-title":"Talquetamab\u202f+\u202fTeclistamab in patients with relapsed\/refractory multiple myeloma: uupdated phase 1b results from RedirecTT-1 with >1 year of follow-up. IMS","volume":"24","author":"Cohen","year":"2024","journal-title":"Rio de Janeiro: Clinical Lymphoma Myeloma and Leukemia"},{"key":"10.1053\/j.seminhematol.2024.12.001_bib0071","series-title":"Characterization of JNJ-79635322, a novel BCMAxGPRC5DxCD3 T-Cell redirecting trispecific antibody, for the treatment of multiple myeloma","first-page":"456","author":"Pillarisetti","year":"2023"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.12.001_bib0072","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1182\/bloodadvances.2022007625","article-title":"Effects of teclistamab and talquetamab on soluble BCMA levels in patients with relapsed\/refractory multiple myeloma","volume":"7","author":"Girgis","year":"2023","journal-title":"Blood Adv"},{"key":"10.1053\/j.seminhematol.2024.12.001_bib0073","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1182\/blood.2024026212","article-title":"Impact of soluble BCMA and non-T-cell factors on refractoriness to BCMA-targeting T-cell engagers in multiple myeloma","volume":"144","author":"Lee","year":"2024","journal-title":"Blood"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.12.001_bib0074","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1158\/2643-3230.BCD-21-0038","article-title":"Tumor burden limits bispecific antibody efficacy through T cell exhaustion averted by concurrent cytotoxic therapy","volume":"2","author":"Meermeier","year":"2021","journal-title":"Blood Cancer Discov"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.12.001_bib0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2023.02.008","article-title":"The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients","volume":"41","author":"Friedrich","year":"2023","journal-title":"Cancer cell"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.12.001_bib0076","doi-asserted-by":"crossref","first-page":"12641","DOI":"10.1038\/s41598-020-69616-5","article-title":"PD-L1 expression in bone marrow plasma cells as a biomarker to predict multiple myeloma prognosis: developing a nomogram-based prognostic model","volume":"10","author":"Lee","year":"2020","journal-title":"Scientific reports"},{"issue":"9","key":"10.1053\/j.seminhematol.2024.12.001_bib0077","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1158\/1078-0432.CCR-19-2299","article-title":"Preclinical activity of JNJ-7957, a novel BCMAxCD3 bispecific antibody for the treatment of multiple myeloma, is potentiated by Daratumumab","volume":"26","author":"Frerichs","year":"2020","journal-title":"Clin Cancer Res: an official journal of the American Association for Cancer Research"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2024.12.001_bib0078","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1182\/blood-2022-162709","article-title":"Teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma (RRMM): ccorrelative analyses from MajesTEC-1","volume":"140","author":"Cortes-Selva","year":"2022","journal-title":"Blood"},{"issue":"7","key":"10.1053\/j.seminhematol.2024.12.001_bib0079","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1182\/bloodadvances.2023011225","article-title":"CD8 effector T cells enhance teclistamab response in BCMA-exposed and -naive multiple myeloma","volume":"8","author":"Firestone","year":"2024","journal-title":"Blood Adv"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2024.12.001_bib0080","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1182\/blood-2023-173550","article-title":"Longitudinal correlative profiles of responders, nonresponders, and those with relapse on treatment with Teclistamab in the phase 1\/2 MajesTEC-1 study of patients with relapsed\/refractory multiple myeloma","volume":"142","author":"Vishwamitra","year":"2023","journal-title":"Blood"},{"issue":"14","key":"10.1053\/j.seminhematol.2024.12.001_bib0081","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1158\/1078-0432.CCR-23-3333","article-title":"T-cell characteristics impact response and resistance to T-cell-redirecting bispecific antibodies in multiple myeloma","volume":"30","author":"Verkleij","year":"2024","journal-title":"Clin Cancer Res: an official journal of the American Association for Cancer Research"},{"issue":"10","key":"10.1053\/j.seminhematol.2024.12.001_bib0082","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1182\/blood.2022015956","article-title":"T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals","volume":"140","author":"Philipp","year":"2022","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2024.12.001_bib0083","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1182\/blood-2022-164717","article-title":"Dysfunctional hyper-expanded clonotypes and lack of TCR clonal replacement predict resistance to T cell engagers in multiple myeloma","volume":"140","author":"Neri","year":"2022","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2024.12.001_bib0084","series-title":"The impact of treatment-free intervals on T-cell exhaustion and clonotypic diversity in myeloma patients treated with BCMA bispecific antibodies","first-page":"1938","author":"Eisele","year":"2023"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2024.12.001_bib0085","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1182\/blood-2023-187755","article-title":"Mechanisms of resistance and relapse with Talquetamab in patients with relapsed\/refractory multiple myeloma from the phase 1\/2 MonumenTAL-1 study","volume":"142","author":"Vishwamitra","year":"2023","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2024.12.001_bib0086","doi-asserted-by":"crossref","first-page":"7054","DOI":"10.1182\/blood-2022-157987","article-title":"Synergistic antitumor activity of Alnuctamab (ALNUC; BMS-986349; CC-93269), a BCMA 2+1 T cell engager (TCE), and Celmod agents in multiple myeloma (MM) preclinical models","volume":"140","author":"Paiva","year":"2022","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2024.12.001_bib0087","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1182\/blood.2024024590","article-title":"Spatial transcriptomics reveals profound subclonal heterogeneity and T-cell dysfunction in extramedullary myeloma","volume":"144","author":"John","year":"2024","journal-title":"Blood"},{"issue":"16_suppl","key":"10.1053\/j.seminhematol.2024.12.001_bib0088","doi-asserted-by":"crossref","first-page":"8045","DOI":"10.1200\/JCO.2023.41.16_suppl.8045","article-title":"Genomic analysis to identify determinants of inherent response and resistance to elranatamab in MagnetisMM-3 cohort A","volume":"41","author":"Bahlis","year":"2023","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.12.001_bib0089","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41408-020-0331-4","article-title":"Blockade of VLA4 sensitizes leukemic and myeloma tumor cells to CD3 redirection in the bone marrow microenvironment","volume":"10","author":"Nair-Gupta","year":"2020","journal-title":"Blood cancer journal"},{"issue":"20","key":"10.1053\/j.seminhematol.2024.12.001_bib0090","doi-asserted-by":"crossref","first-page":"5591","DOI":"10.1158\/1078-0432.CCR-12-3676","article-title":"Accessory cells of the microenvironment protect multiple myeloma from T-cell cytotoxicity through cell adhesion-mediated immune resistance","volume":"19","author":"de Haart","year":"2013","journal-title":"Clin Cancer Res: an official journal of the American Association for Cancer Research"},{"issue":"19","key":"10.1053\/j.seminhematol.2024.12.001_bib0091","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1182\/bloodadvances.2019000600","article-title":"T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma","volume":"3","author":"Garfall","year":"2019","journal-title":"Blood Adv"},{"issue":"7","key":"10.1053\/j.seminhematol.2024.12.001_bib0092","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1182\/bloodadvances.2020003857","article-title":"Microenvironment immune reconstitution patterns correlate with outcomes after autologous transplant in multiple myeloma","volume":"5","author":"Parmar","year":"2021","journal-title":"Blood Adv"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2024.12.001_bib0093","doi-asserted-by":"crossref","first-page":"10172","DOI":"10.1182\/blood-2022-166854","article-title":"Magnetismm-4: aan open label, phase 1B\/2 umbrella study of Elranatamab in combination with other anti-cancer treatments for patients with multiple myeloma","volume":"140","author":"Landgren","year":"2022","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2024.12.001_bib0094","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1182\/blood-2021-148723","article-title":"Subcutaneous Teclistamab in combination with Daratumumab for the treatment of patients with relapsed\/refractory multiple myeloma: rresults from a phase 1b multicohort study","volume":"138","author":"Rodriguez-Otero","year":"2021","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2024.12.001_bib0095","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1182\/blood-2022-159711","article-title":"Teclistamab in combination with subcutaneous Daratumumab and Lenalidomide in patients with multiple myeloma: rresults from one cohort of MajesTEC-2, a Phase1b, multicohort study","volume":"140","author":"Searle","year":"2022","journal-title":"Blood"},{"issue":"16_suppl","key":"10.1053\/j.seminhematol.2024.12.001_bib0096","doi-asserted-by":"crossref","first-page":"TPS8072","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS8072","article-title":"MajesTEC-3: rrandomized, phase 3 study of teclistamab plus daratumumab versus investigator's choice of daratumumab, pomalidomide, and dexamethasone or daratumumab, bortezomib, and dexamethasone in patients with relapsed\/refractory multiple myeloma","volume":"40","author":"Mateos","year":"2022","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10.1053\/j.seminhematol.2024.12.001_bib0097","doi-asserted-by":"crossref","first-page":"7506","DOI":"10.1200\/JCO.2024.42.16_suppl.7506","article-title":"Safety results from the phase 3 MajesTEC-7 study in patients (pts) with transplant ineligible\/not intended newly diagnosed multiple myeloma (NDMM)","volume":"42","author":"Touzeau","year":"2024","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2024.12.001_bib0098","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1182\/blood-2023-187706","article-title":"Talquetamab\u202f+\u202fPomalidomide in patients with relapsed\/refractory multiple myeloma: ssafety and preliminary efficacy results from the phase 1b MonumenTAL-2 study","volume":"142","author":"Matous","year":"2023","journal-title":"Blood"},{"issue":"16_suppl","key":"10.1053\/j.seminhematol.2024.12.001_bib0099","doi-asserted-by":"crossref","first-page":"TPS8074","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS8074","article-title":"MagnetisMM-5: aan open-label, multicenter, randomized phase 3 study of elranatamab as monotherapy and in combination with daratumumab in patients with relapsed\/refractory multiple myeloma","volume":"40","author":"Grosicki","year":"2022","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10.1053\/j.seminhematol.2024.12.001_bib0100","doi-asserted-by":"crossref","first-page":"8003","DOI":"10.1200\/JCO.2023.41.16_suppl.8003","article-title":"Talquetamab (tal)\u202f+\u202fdaratumumab (dara) in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): uupdated TRIMM-2 results","volume":"41","author":"Dholaria","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2024.12.001_bib0101","first-page":"210","article-title":"Talquetamab (tal)\u202f+\u202fDaratumumab (dara)\u202f+\u202fPomalidomide (pom) in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): rresults from the phase 1b TRIMM-2 study","volume":"24","author":"Bahlis","year":"2024","journal-title":"IMS. Rio de Janeiro: Clinical Lymphoma Myeloma and Leukemia"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.12.001_bib0102","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","article-title":"Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma","volume":"128","author":"Krejcik","year":"2016","journal-title":"Blood"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.12.001_bib0103","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1139662","article-title":"Lenalidomide enhances myeloma-specific T-cell responses in vivo and in vitro","volume":"5","author":"Kramer","year":"2016","journal-title":"Oncoimmunology"},{"issue":"17","key":"10.1053\/j.seminhematol.2024.12.001_bib0104","doi-asserted-by":"crossref","first-page":"4195","DOI":"10.1182\/bloodadvances.2020002524","article-title":"The immunomodulatory drugs lenalidomide and pomalidomide enhance the potency of AMG 701 in multiple myeloma preclinical models","volume":"4","author":"Cho","year":"2020","journal-title":"Blood Adv"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.12.001_bib0105","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1084\/jem.145.2.455","article-title":"Cyclophosphamide-sensitive T lymphocytes suppress the in vivo generation of antigen-specific cytotoxic T lymphocytes","volume":"145","author":"Rollinghoff","year":"1977","journal-title":"J Exp Med"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.12.001_bib0106","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1158\/0008-5472.CAN-10-2788","article-title":"Cyclophosphamide synergizes with type I interferons through systemic dendritic cell reactivation and induction of immunogenic tumor apoptosis","volume":"71","author":"Schiavoni","year":"2011","journal-title":"Cancer research"},{"key":"10.1053\/j.seminhematol.2024.12.001_bib0107","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.3389\/fimmu.2018.02204","article-title":"Checkpoint inhibition in Myeloma: oopportunities and challenges","volume":"9","author":"Costa","year":"2018","journal-title":"Front immunol"},{"issue":"23","key":"10.1053\/j.seminhematol.2024.12.001_bib0108","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in patients with relapsed or refractory hematologic malignancy: ppreliminary results of a phase ib study","volume":"34","author":"Lesokhin","year":"2016","journal-title":"J Clin Oncol: official journal of the American Society of Clinical Oncology"},{"key":"10.1053\/j.seminhematol.2024.12.001_bib0109","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1038\/s43018-024-00818-w","article-title":"Clinical response and pathway-specific correlates following TIGIT-LAG3 blockade in myeloma: the MyCheckpoint randomized clinical trial","volume":"5","author":"Richard","year":"2024","journal-title":"Nat Cancer"},{"key":"10.1053\/j.seminhematol.2024.12.001_bib0110","first-page":"8036","article-title":"Pivotal phase 2 MonumenTAL-1 results of talquetamab, a GPRC5D\u00d7 CD3 bispecific antibody, for relapsed\/refractory multiple myeloma","volume":"41","author":"Schinke","year":"2023","journal-title":"ASCO. Chicago: J Clin Oncol"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2024.12.001_bib0111","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.1182\/blood-2022-157547","article-title":"Enduring responses after 1-year, fixed-duration Cevostamab therapy in patients with relapsed\/refractory multiple myeloma: eearly experience from a phase I study","volume":"140","author":"Lesokhin","year":"2022","journal-title":"Blood"},{"issue":"16_suppl","key":"10.1053\/j.seminhematol.2024.12.001_bib0112","doi-asserted-by":"crossref","first-page":"7536-","DOI":"10.1200\/JCO.2024.42.16_suppl.7536","article-title":"Real-world schedule de-escalation of teclistamab in patients with relapsed\/refractory multiple myeloma","volume":"42","author":"Tan","year":"2024","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.12.001_bib0113","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1182\/bloodadvances.2022007923","article-title":"Sequencing T-cell redirection therapies leads to deep and durable responses in patients with relapsed\/refractory myeloma","volume":"7","author":"Mouhieddine","year":"2023","journal-title":"Blood Adv"},{"issue":"7","key":"10.1053\/j.seminhematol.2024.12.001_bib0114","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1182\/blood.2022017848","article-title":"Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy","volume":"141","author":"Van Oekelen","year":"2023","journal-title":"Blood"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.12.001_bib0115","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood.2022015526","article-title":"Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents","volume":"141","author":"Cohen","year":"2023","journal-title":"Blood"},{"issue":"11","key":"10.1053\/j.seminhematol.2024.12.001_bib0116","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1200\/JCO.22.01365","article-title":"Idecabtagene Vicleucel for relapsed\/refractory multiple myeloma: rreal-world experience from the Myeloma CAR T Consortium","volume":"41","author":"Hansen","year":"2023","journal-title":"J Clin Oncol: official journal of the American Society of Clinical Oncology"},{"issue":"16_suppl","key":"10.1053\/j.seminhematol.2024.12.001_bib0117","doi-asserted-by":"crossref","first-page":"8008","DOI":"10.1200\/JCO.2023.41.16_suppl.8008","article-title":"Efficacy and safety of elranatamab in patients with relapsed\/refractory multiple myeloma (RRMM) and prior B-cell maturation antigen (BCMA)-directed therapies: a pooled analysis from MagnetisMM studies","volume":"41","author":"Nooka","year":"2023","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1053\/j.seminhematol.2024.12.001_bib0118","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1182\/bloodadvances.2023012066","article-title":"Salvage therapies including retreatment with BCMA-directed approaches after BCMA CAR-T relapses for multiple myeloma","volume":"8","author":"Reyes","year":"2024","journal-title":"Blood Adv"},{"key":"10.1053\/j.seminhematol.2024.12.001_bib0119","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood.2023023616","article-title":"Efficacy and safety of teclistamab in patients with relapsed\/refractory multiple myeloma after BCMA-targeting therapies","volume":"144","author":"Touzeau","year":"2024","journal-title":"Blood"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.12.001_bib0120","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/s41375-024-02154-5","article-title":"Real-world analysis of teclistamab in 123 RRMM patients from Germany","volume":"38","author":"Riedhammer","year":"2024","journal-title":"Leukemia"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.12.001_bib0121","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2023.12.016","article-title":"Safety and efficacy of Teclistamab in patients with relapsed\/refractory multiple myeloma: a real-world experience","volume":"30","author":"Dima","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2024.12.001_bib0122","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1182\/blood-2023-187242","article-title":"Updated results of Talquetamab, a GPRC5D\u00d7CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma with prior exposure to T-cell redirecting therapies: rresults of the phase 1\/2 MonumenTAL-1 study","volume":"142","author":"Jakubowiak","year":"2023","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2024.12.001_bib0123","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1182\/blood-2023-182330","article-title":"Clinical outcomes of subsequent therapies in patients with relapsed\/refractory multiple myeloma following Talquetamab treatment: aanalyses from the phase 1\/2 MonumenTAL-1 study","volume":"142","author":"Sanchez","year":"2023","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2024.12.001_bib0124","series-title":"Sequential administration of bispecific antibodies and anti-BCMA CAR-T cell therapy in relapsed\/refractory multiple myeloma is associated with expansion of CD8 effector clones and high response rates. EHA","author":"Fandrei","year":"2024"},{"issue":"13","key":"10.1053\/j.seminhematol.2024.12.001_bib0125","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1002\/cncr.34756","article-title":"Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTEC-1 study of patients with relapsed\/refractory multiple myeloma","volume":"129","author":"Martin","year":"2023","journal-title":"Cancer"},{"issue":"19","key":"10.1053\/j.seminhematol.2024.12.001_bib0126","doi-asserted-by":"crossref","first-page":"5898","DOI":"10.1182\/bloodadvances.2023010539","article-title":"Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis","volume":"7","author":"Reynolds","year":"2023","journal-title":"Blood Adv"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.12.001_bib0127","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41408-023-00879-7","article-title":"Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel","volume":"13","author":"Raje","year":"2023","journal-title":"Blood Cancer J"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.12.001_bib0128","doi-asserted-by":"crossref","first-page":"e205","DOI":"10.1016\/S1470-2045(24)00043-3","article-title":"International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma","volume":"25","author":"Rodriguez-Otero","year":"2024","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1053\/j.seminhematol.2024.12.001_bib0129","article-title":"Clinical management of patients with relapsed\/refractory multiple myeloma treated with Talquetamab","volume":"24","author":"Chari","year":"2024","journal-title":"Clin Lymph, Myeloma Leukemia"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196324001422?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196324001422?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T10:08:07Z","timestamp":1741946887000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196324001422"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":129,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S0037196324001422"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2024.12.001","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advancements in bispecific antibodies for multiple myeloma: What's new and what lies ahead","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2024.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}